EPC-002

About Elpis Biopharmaceuticals

Elpis Biopharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with an additional presence in Singapore. The company is focused on developing novel bispecific armored CAR-T cell therapies and immuno-modulators to treat solid tumors, a significant unmet medical need. Its core strategy leverages proprietary platforms for multi-antigen targeting and armored cell engineering to improve efficacy and durability. Elpis's lead programs target glioblastoma and a broad range of solid tumors, positioning it in the competitive but high-potential field of next-generation cell therapy.

Therapeutic Areas